NASDAQ:SRGA • US86882C2044
The current stock price of SRGA is 0.1829 USD. In the past month the price decreased by -75.93%. In the past year, price decreased by -94.35%.
ChartMill assigns a fundamental rating of 1 / 10 to SRGA. SRGA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SRGA reported a non-GAAP Earnings per Share(EPS) of -5.81. The EPS increased by 50.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
10 analysts have analysed SRGA and the average price target is 2.3 USD. This implies a price increase of 1154.78% is expected in the next year compared to the current price of 0.1829.
For the next year, analysts expect an EPS growth of -58.25% and a revenue growth -37.13% for SRGA
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 30.42 | 58.526B | ||
| COO | COOPER COS INC/THE | 17.95 | 16.264B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.71 | 13.401B | ||
| SOLV | SOLVENTUM CORP | 11.43 | 13.104B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.9 | 4.842B | ||
| LNTH | LANTHEUS HOLDINGS INC | 12.48 | 4.601B | ||
| ICUI | ICU MEDICAL INC | 18.13 | 3.578B | ||
| HAE | HAEMONETICS CORP/MASS | 10.7 | 2.684B | ||
| XRAY | DENTSPLY SIRONA INC | 8.02 | 2.584B | ||
| NEOG | NEOGEN CORP | 32.3 | 2.38B |
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. The company is headquartered in Deerfield, Illinois and currently employs 217 full-time employees. The company went IPO on 2000-08-10. The firm is focused on developing artificial intelligence (AI) and augmented reality (AR) technology platform called HOLO AI, which is an AI software technology, which connects the continuum of care from the pre-op and clinical-stage through post-op care. Its HOLO Portal surgical guidance system, a component of its HOLO AI technology platform, is designed to automatically recognize, identify, and segment patient anatomy to autonomously assist the surgeon throughout the surgical procedure. The company has a portfolio of spinal hardware implants, including solutions for fusion procedures in the lumbar, thoracic, and cervical spine, motion, and a minimally invasive surgical implant system for fusion of the sacroiliac joint. The company also has a biomaterials portfolio of advanced and traditional orthobiologics. Its market and sell products to hospitals, ambulatory surgery centers, and healthcare providers in the United States.
SURGALIGN HOLDINGS INC
520 Lake Cook Rd Ste 315
Deerfield ILLINOIS 60015 US
CEO: Terry M. Rich
Employees: 217
Phone: 18773436832.0
Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. The company is headquartered in Deerfield, Illinois and currently employs 217 full-time employees. The company went IPO on 2000-08-10. The firm is focused on developing artificial intelligence (AI) and augmented reality (AR) technology platform called HOLO AI, which is an AI software technology, which connects the continuum of care from the pre-op and clinical-stage through post-op care. Its HOLO Portal surgical guidance system, a component of its HOLO AI technology platform, is designed to automatically recognize, identify, and segment patient anatomy to autonomously assist the surgeon throughout the surgical procedure. The company has a portfolio of spinal hardware implants, including solutions for fusion procedures in the lumbar, thoracic, and cervical spine, motion, and a minimally invasive surgical implant system for fusion of the sacroiliac joint. The company also has a biomaterials portfolio of advanced and traditional orthobiologics. Its market and sell products to hospitals, ambulatory surgery centers, and healthcare providers in the United States.
The current stock price of SRGA is 0.1829 USD. The price decreased by -32.98% in the last trading session.
SRGA does not pay a dividend.
SRGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
10 analysts have analysed SRGA and the average price target is 2.3 USD. This implies a price increase of 1154.78% is expected in the next year compared to the current price of 0.1829.
The Revenue of SURGALIGN HOLDINGS INC (SRGA) is expected to decline by -37.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SURGALIGN HOLDINGS INC (SRGA) has a market capitalization of 1.68M USD. This makes SRGA a Nano Cap stock.